![]()
Working group : J.F. Rey (St. Laurent du Var)
- A. Budzynska (Katowice)
- A. Axon (Leeds)
- A. Kruse (Aarhus)
- A. Nowak (Katowice)
12/1/98
The prevention of:
|
|
|
| procedure | patients risk group | antibiotic prophylaxis |
|---|---|---|
| high risk procedures: | high risk patients | regimen A or B |
| oesophageal dilation | severe neutropenia | regimen A or B plus C |
| variceal sclerosis | moderate risk patients | not necessary |
| laser therapy in upper GI | regimen A or B | |
| may be considered | |
| low or average risk patients | not recommended | |
| low risk procedures: | high risk patients | not necessary |
|
| regimen A or B |
| may be considered | |
| moderate or low risk patients | not recommended |
| ERCP | biliary occlusion pancreatic pseudocyst previous cholangitis or | regimen C |
| PEG | all patients | regimen D |
| A. Patients not allergic to penicillin.
Adults:
Children under 10 years: |
| B. Patients allergic to penicillin or who have had penicillin
more than once in the previous month.
Adults:
Children under 10 years: |
| C. Prior to biliary procedures.
750 mg ciprofloxacin orally 60-90 minutes before the procedure |
| D. Prior to percutaneous endoscopic gastrostomy
2 g cefotaxime (or equivalent) parenterally 30 minutes before the procedure |
| E. Patients with severe neutropenia
Adults:
Children: |